HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Haas, C. J. C. Articles by Van Strijp, J. A. G. Search for Related Content PubMed PubMed Citation Articles by de Haas, C. J. C. Articles by Van Strijp, J. A. G.

A Synthetic Lipopolysaccharide-Binding Peptide Based on Amino Acids 27–39 of Serum Amyloid P Component Inhibits Lipopolysaccharide-Induced Responses in Human Blood

Eijkman Winkler Institute, Department of Inflammation, Utrecht, The Netherlands

LPS-binding proteins in plasma play an important role in modifying LPS toxicity. Significant properties have already been attributed to the LPS-binding protein (LBP). It accelerates LPS toxicity as well as incorporation into high-density lipoproteins, leading to neutralization of LPS in serum. A search for other LPS-binding components in serum, using LPS-coated magnetic beads, revealed a new LPS-binding protein. N-terminal microsequencing identified this protein as serum amyloid P component (SAP). Purified SAP bound to smooth and rough types of LPS via the lipid A part. SAP inhibited the binding of FITC-labeled ReLPS (LPS from Salmonella minnesota strain R595) to human monocytes and the ReLPS-induced priming of the oxidative burst of human neutrophils only in the presence of low concentrations of LBP. In search for the LPS binding site of SAP, we found that pep27–39, a 13-mer peptide consisting of amino acids 27–39 of SAP, competitively inhibited the binding of LPS to SAP. In addition, pep27–39 significantly inhibited ReLPS-induced responses in phagocytes in the presence of serum, as well as in human whole blood. Carboxamidomethylated pep27–39 showed an even more pronounced reduction of the ReLPS-induced priming of phagocytes in human blood. Performing gel filtration of FITC-labeled ReLPS incubated with soluble CD14, we showed that SAP could not prevent binding of LPS to soluble CD14, in contrast to pep27–39. The ability of pep27–39 to antagonize specifically the effects of LPS in the complex environment of human blood suggests that pep27–39 may be a novel therapeutic agent in the treatment of Gram-negative sepsis.

This article has been cited by other articles:

				M. Satoh, T. Iwahori, N. Sugawara, and M. Yamazaki Liver argininosuccinate synthase binds to bacterial lipopolysaccharides and lipid A and inactivates their biological activities Innate Immunity, February 1, 2006; 12(1): 21 - 38. [Abstract] [PDF]

				C. Li, M. L. P. Ng, Y. Zhu, B. Ho, and J. L. Ding Tandem repeats of Sushi3 peptide with enhanced LPS-binding and -neutralizing activities Protein Eng. Des. Sel., August 1, 2003; 16(8): 629 - 635. [Abstract] [Full Text] [PDF]

				E. S. Van Amersfoort, T. J. C. Van Berkel, and J. Kuiper Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock Clin. Microbiol. Rev., July 1, 2003; 16(3): 379 - 414. [Abstract] [Full Text] [PDF]

				C. Alexander and E. Th. Rietschel Invited review: Bacterial lipopolysaccharides and innate immunity Innate Immunity, June 1, 2001; 7(3): 167 - 202. [Abstract] [PDF]

				M. Noursadeghi, M. C. M. Bickerstaff, J. R. Gallimore, J. Herbert, J. Cohen, and M. B. Pepys Role of serum amyloid P component in bacterial infection: Protection of the host or protection of the pathogen PNAS, December 19, 2000; 97(26): 14584 - 14589. [Abstract] [Full Text] [PDF]

				C. J. C. de Haas, M. J. J. G. Poppelier, K. P. M. van Kessel, and J. A. G. van Strijp Serum Amyloid P Component Prevents High-Density Lipoprotein-Mediated Neutralization of Lipopolysaccharide Infect. Immun., September 1, 2000; 68(9): 4954 - 4960. [Abstract] [Full Text] [PDF]

				C. J. C. de Haas, E. M. M. van Leeuwen, T. van Bommel, J. Verhoef, K. P. M. van Kessel, and J. A. G. van Strijp Serum Amyloid P Component Bound to Gram-Negative Bacteria Prevents Lipopolysaccharide-Mediated Classical Pathway Complement Activation Infect. Immun., April 1, 2000; 68(4): 1753 - 1759. [Abstract] [Full Text] [PDF]

				C. J. C. de Haas, R. van der Zee, B. Benaissa-Trouw, K. P. M. van Kessel, J. Verhoef, and J. A. G. van Strijp Lipopolysaccharide (LPS)-Binding Synthetic Peptides Derived from Serum Amyloid P Component Neutralize LPS Infect. Immun., June 1, 1999; 67(6): 2790 - 2796. [Abstract] [Full Text] [PDF]